ClinicalTrials.gg
CompletedNCT02677896ARCHESUpdated Oct 24, 2025Results posted

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

A Phase 3 interventional study of Enzalutamide and Placebo in Metastatic Hormone Sensitive Prostate Cancer, sponsored by Astellas Pharma Global Development, Inc.. Completed at 203 sites in 24 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-24.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,150
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
7th of 125
1,150 · median 52
Started
2016
with 8 others
Phase 3
16 of 125
1 open now
Registered
62nd of 125
by date
Lead sponsor
6 of 125
Astellas Pharma Global Development, Inc.

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 7th largest by enrollment, is one of 9 that started in 2016, is one of 16 in phase 3, and was the 62nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the efficacy of enzalutamide plus androgen deprivation therapy (ADT) as measured by radiographic progression-free survival (rPFS) based on central review. The study also evaluated the safety of enzalutamide plus ADT in mHSPC.

Read the detailed description

Following unblinding at the end of the double-blind period and demonstration of a statistically significant advantage of enzalutamide over placebo when added to ADT as assessed by the primary endpoint of rPFS, subjects were eligible to transition to an open-label portion of the study.

03

Conditions studied

  • Metastatic Hormone Sensitive Prostate Cancer

Browse trials for

Keywords

  • Androgen Deprivation Therapy (ADT)
  • Metastatic hormone sensitive prostate cancer
  • Xtandi
  • Enzalutamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Subject is considered an adult according to local regulation at the time of signing .
  • Subject is diagnosed with or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.
  • Subject has prostate cancer documented by positive bone scan (for bone disease) or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI) scan (for soft tissue). Subjects whose disease spread is limited to regional pelvic lymph nodes are not eligible.
  • Once randomized at day 1, subject must maintain ADT with an LHRH agonist or antagonist during study treatment or have a history of bilateral orchiectomy (i.e., medical or surgical castration).
  • Subject has an (ECOG) performance status of 0 or 1.

Inclusion Criteria for Open-Label Extension:

  • Subject received randomized double-blind treatment in ARCHES
  • Subject has not met any of the discontinuation criteria in the main ARCHES protocol
  • Subject is willing to maintain ADT with LHRH agonist or antagonist or has had a bilateral orchiectomy.
  • Subject is able to swallow enzalutamide capsules whole and to comply with study requirements throughout the study
  • Subject and subject's female partner agree to follow and sperm donation requirements in main protocol

Exclusion Criteria:

  • Subject has received any prior pharmacotherapy, radiation therapy or surgery for metastatic prostate cancer (the following exceptions are permitted):

    • Up to 3 months of ADT with LHRH agonists or antagonists or orchiectomy with or without concurrent antiandrogens prior to day 1, with no radiographic evidence of disease progression or rising PSA levels prior to day 1;
    • Subject may have 1 course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease if it was administered at least 4 weeks prior to day 1;
    • Up to 6 cycles of docetaxel therapy with final treatment administration completed within 2 months of day 1 and no evidence of disease progression during or after the completion of docetaxel therapy;
    • Up to 6 months of ADT with LHRH agonists or antagonists or orchiectomy with or without concurrent antiandrogens prior to day 1 if subject was treated with docetaxel, with no radiographic evidence of disease progression or rising PSA levels prior to day 1;
    • Prior ADT given for \< 39 months in duration and > 9 months before randomization as /adjuvant therapy.
  • Subject had a major surgery within 4 weeks prior to day 1.
  • Subject received treatment with 5-α reductase inhibitors (finasteride, dutasteride) within 4 weeks prior to day 1.
  • Subject received treatment with estrogens, cyprotoerone acetate or androgens within 4 weeks prior to day 1.
  • Subject received treatment with systemic greater than the equivalent of 10 mg per day of prednisone within 4 weeks prior to day 1, intended for the treatment of prostate cancer.
  • Subject received treatment with herbal medications that have known hormonal antiprostate cancer activity and/or are known to decrease PSA levels within 4 weeks prior to day 1.
  • Subject received prior aminoglutethimide, ketoconazole, abiraterone acetate or enzalutamide for the treatment of prostate cancer or participation in a clinical study of an agent that inhibits the AR or androgen synthesis (e.g., TAK-700, ARN-509, ODM-201).
  • Subject has known or suspected or active .
  • Subject has \< 1500/μL, count \< 100000/μL or \< 10 g/dL (6.2 mmol/L).
  • Subject has total (TBL) ≥ 1.5 x the (ULN) (except subjects with documented Gilbert's disease), or (ALT) or aspartate aminotransferase (AST) ≥ 2.5 x the ULN .
  • Subject has creatinine > 2 mg/dL (177 μmol/L).
  • Subject has albumin \< 3.0 g/dL (30 g/L).
  • Subject has a history of seizure or any condition that may predispose to seizure.
  • Subject has history of loss of consciousness or within 12 months prior to day 1.
  • Subject has cardiovascular disease.
  • Subject received bisphosphonates or denosumab within 2 weeks prior to day 1 unless administered at stable dose or to treat diagnosed osteoporosis

Exclusion Criteria for Open-Label Extension:

  • Subject has taken commercially available enzalutamide (Xtandi).
  • Subject's disease has progressed radiographically during the double-blind period of the study and treatment with study drug was stopped prior to study-wide unblinding. (Note: Subjects who progressed radiographically while in the double-blind portion of the study and continued treatment per protocol are allowed to participate in the open label extension.)
  • After study-wide unblinding, subject has started any new investigational agent or anti-neoplastic therapy intended to treat prostate cancer
  • Subject has any clinically significant disorder or condition including excessive alcohol or drug abuse, or secondary , which may interfere with study participation
  • Subject has current or previously treated brain metastasis or active leptomeningeal disease
  • Subject has a history of seizure or any condition that may increase the risk of seizure
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,150 participants (actual)

Study arms

  • Experimental
    Enzalutamide + Androgen Deprivation Therapy (ADT)

    Participants received 160 mg enzalutamide orally once daily during double-blind treatment period until radiographic progression was documented or until the participants started an investigational agent or new therapy for treatment of prostate cancer or until any other discontinuation criterion was met. Eligible participants who received enzalutamide during double-blind treatment period and provided informed consent to take part in open-label period continued to receive 160 mg enzalutamide orally once daily in open-label period until disease progression, unacceptable toxicity or any other discontinuation criteria were met. ADT (either bilateral orchiectomy or Luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.

    Drug: Enzalutamide

  • Placebo comparator
    Placebo + Androgen Deprivation Therapy (ADT)

    Participants received matching placebo orally once daily during double-blind treatment period until radiographic progression was documented or until the participants started an investigational agent or new therapy for treatment of prostate cancer or until any other discontinuation criterion was met. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.

    Drug: Placebo

  • Experimental
    Placebo followed by Enzalutamide

    Eligible participants who received enzalutamide matching placebo during double-blind treatment period and provided informed consent to take part in open-label period switched to receive 160 mg enzalutamide orally once daily in open-label period until disease progression, unacceptable toxicity or any other discontinuation criteria were met. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.

    Drug: Enzalutamide

Interventions

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-Free Survival (rPFS) Based on Independent Central Review (ICR) of Bone Scan According to Prostate Cancer Clinical Trials Working Group 2 (PCWG2) Criteria

    rPFS was calculated as the time from the date of randomization to the first objective evidence of radiographic progression disease (rPD) at any time or death up to 24 weeks after study drug discontinuation without documented radiographic progression, whichever occurred first. rPD was defined as progressive disease by Response Evaluation Criteria in Solid Tumors version 1.1 for soft tissue disease or by appearance of 2 or more new lesions on bone scan compared to baseline or week 13 according to PCWG2 criteria, as assessed by ICR or death. In participants with no rPFS event, rPFS was censored on the date of last evaluable radiographic assessment prior to the data analysis cutoff date. In participants with no baseline radiographic assessment, participants with no postbaseline radiographic assessments and participants with all postbaseline radiographic assessments documented as "not evaluable (NE)," rPFS was censored on the date of randomization.

    Time frame: From the date of randomization to the first objective evidence of rPD at any time or death (maximum duration was 26.6 months)

  2. rPFS Based on ICR of Bone Scan According to Protocol Assessment Criteria

    rPFS was calculated as the time from the date of randomization to the first objective evidence of radiographic progression disease (rPD) at any time or death up to 24 weeks after study drug discontinuation without documented radiographic progression, whichever occurred first. rPD was defined as progressive disease by Response Evaluation Criteria in Solid Tumors version 1.1 for soft tissue disease or by appearance of 2 or more new lesions on bone scan compared to baseline for week 13 or the best response on treatment for week 25 or later assessments, as assessed by ICR or death. In participants with no rPFS event, rPFS was censored on the date of last evaluable radiographic assessment prior to the data analysis cutoff date. In participants with no baseline radiographic assessment, participants with no postbaseline radiographic assessments and participants with all postbaseline radiographic assessments documented as "not evaluable (NE)," rPFS was censored on the date of randomization.

    Time frame: From the date of randomization to the first objective evidence of rPD at any time or death (maximum duration was 26.6 months)

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause. In participants still alive at the date of the analysis cutoff point, OS was censored on the last date the participant was known to be alive. OS was analyzed using Kaplan-Meier estimates.

    Time frame: From randomization to death due to any cause (maximum duration was 58.6 months)

  2. Time to Prostate Specific Antigen (PSA) Progression

    Time to PSA progression was calculated as the time from the date of randomization to the first observation of PSA progression. A PSA progression was defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir, which was confirmed by a second consecutive value at least 3 weeks later. In participants with no PSA progression, time to PSA progression was censored on the date of the last PSA sample taken (or last value prior to 2 or more consecutive missed PSA assessments).

    Time frame: From the date of randomization to the first observation of PSA progression (maximum duration was 26.6 months)

  3. Time to Start of New Antineoplastic Therapy

    In participants with a new antineoplastic therapy initiated for prostate cancer after randomization, time to start of a new antineoplastic therapy was defined as the time interval from randomization to the date of the first dose administration of the first antineoplastic therapy. In participants with no new antineoplastic therapy initiated for prostate cancer after randomization, time to start of new antineoplastic therapy was censored on the last visit date or the date of randomization, whichever occurred last. Time to start of new antineoplastic therapy was analyzed using Kaplan-Meier estimates.

    Time frame: From randomization to the date of the first dose administration of the first antineoplastic therapy (maximum duration was 58.6 months)

  4. PSA Undetectable Rate

    The PSA undetectable rate was defined as the percentage of participants with undetectable (\< 0.2 ng/mL) PSA values at any time during study treatment, of those participants with detectable (≥ 0.2 ng/mL) PSA values at baseline.

    Time frame: From baseline to detectable PSA values (maximum duration was 26.6 months)

  5. Objective Response Rate (ORR)

    The ORR was calculated as the percentage of participants who achieved a completed response (CR) or a partial response (PR) (unconfirmed responses) in their soft tissue disease using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by ICR.

    Time frame: From date of randomization up to 26.6 months

  6. Time to Deterioration in Urinary Symptoms

    In participants with deterioration, the time to deterioration was calculated as the time interval between randomization and the first deterioration in urinary symptoms at any postbaseline visit. A deterioration in urinary symptoms was defined as an increase in the Quality of Life Prostate-specific Questionnaire (QLQ-PR25) modified urinary symptoms. Subscale score by ≥ 50% of the standard deviation observed in the QLQ-PR25 modified urinary symptoms subscale score at baseline. Modified urinary symptoms subscale score consisted of 3-items (Q31 - Q33) from the QLQ-PR25, each scored from 1 (not at all) to 4 (very much). The total modified urinary symptoms subscale score ranges from 0-100, with higher scores represents a higher level of symptomatology/problems. In participants without deterioration in urinary symptoms, the time to deterioration in urinary symptoms was censored on the date the last urinary symptoms QLQ-PR25 score was calculable.

    Time frame: From date of randomization to the first deterioration in urinary symptoms at any postbaseline visit (maximum duration was 26.6 months)

  7. Time to First Symptomatic Skeletal Event (SSE)

    Time to first SSE was calculated as the time from randomization to the occurrence of the first SSE. An SSE was defined as radiation to bone, surgery to bone, clinically apparent pathological bone fracture, or spinal cord compression. In participants with no SSE, time to SSE was censored on the last visit date or the date of randomization, whichever occurred last.

    Time frame: From randomization to the occurrence of the first SSE (maximum duration was 26.6 months)

  8. Time to Castration Resistance

    Time to castration resistance was calculated as the time from randomization to the first castration-resistant event. A castration resistance event was defined as any of the following in the presence of castrate levels of testosterone (\< 50 ng/dL): radiographic disease progression, PSA progression or SSE, whichever occurred first. In participants with no documented castration resistance event, the time to castration resistance was censored on the latest date from: the date of last radiologic assessment, the last PSA sample taken prior to the start of any new prostate cancer therapy and prior to 2 or more consecutive missed PSA assessments (if applicable), and the last visit date performed.

    Time frame: From randomization to the first castration-resistant event (maximum duration was 26.6 months)

  9. Time to Deterioration of Quality of Life (QoL) in Functional Assessment of Cancer Therapy-Prostate (FACT-P)

    Time to deterioration of QoL was calculated as the time interval from the date of randomization to the first date a decline from baseline of 10 points or more in the FACT-P total score was recorded. The FACT-P consists of 27 core items that assess participant function in 4 domains and 12 prostate cancer-related items grouped into 5 subscales as follows: physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing and prostate cancer subscale. Each item is rated on a 0 to 4 Likert-type scale. The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0 to 156), where high score represent better quality of life. In participants without FACT-P progression, the time to deterioration of QoL was censored on the date of the last FACT-P total score was calculable.

    Time frame: From the date of randomization to the first date a decline from baseline of 10 points or more in the FACT-P total score (maximum duration was 26.6 months)

  10. Time to Pain Progression Based on Brief Pain Inventory-Short Form (BPI-SF)

    Time to pain progression was defined as time from randomization to the first pain progression event. Pain progression was defined as an increase of ≥ 30% from baseline in the average BPI-SF pain severity score. BPI-SF contains 9 questions with rating scales from 0 (no pain/no interference) to 10 (worst pain/interferes completely). Total score was calculated as the average of each question. Higher scores represent a higher level of pain or interference. In participants with no pain progression event, time to pain progression was censored on the last visit date where BPI-SF was collected.

    Time frame: From randomization to the first pain progression event (maximum duration was 26.6 months)

07

Results

Posted Jan 21, 2020

Participant flow

Participants with metastatic hormone sensitive prostate cancer (mHSPC) were enrolled in 204 study sites worldwide.

Double Blind Period (up to 35 Months)
Participant flow — Double Blind Period (up to 35 Months)
MilestoneEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)
Started574576
Treated572574
Completed00
Not completed574576
Withdrew: Death117197
Withdrew: Lost to follow-up1215
Withdrew: Progressive disease36
Withdrew: Withdrawal by subject4171
Withdrew: Miscellaneous3099
Withdrew: Continued in ole370182
Withdrew: Discontinued by sponsor14
Withdrew: Randomized, not treated02
Open-Label Extension (Approx. 66 Months)
Participant flow — Open-Label Extension (Approx. 66 Months)
MilestoneEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)
Started370182
Completed00
Not completed370182
Withdrew: Death7326
Withdrew: Lost to follow-up83
Withdrew: Progressive disease2210
Withdrew: Withdrawal by subject1613
Withdrew: Miscellaneous241125
Withdrew: Discontinued by sponsor105

Outcome measures

PrimaryRadiographic Progression-Free Survival (rPFS) Based on Independent Central Review (ICR) of Bone Scan According to Prostate Cancer Clinical Trials Working Group 2 (PCWG2) Criteria

rPFS was calculated as the time from the date of randomization to the first objective evidence of radiographic progression disease (rPD) at any time or death up to 24 weeks after study drug discontinuation without documented radiographic progression, whichever occurred first. rPD was defined as progressive disease by Response Evaluation Criteria in Solid Tumors version 1.1 for soft tissue disease or by appearance of 2 or more new lesions on bone scan compared to baseline or week 13 according to PCWG2 criteria, as assessed by ICR or death. In participants with no rPFS event, rPFS was censored on the date of last evaluable radiographic assessment prior to the data analysis cutoff date. In participants with no baseline radiographic assessment, participants with no postbaseline radiographic assessments and participants with all postbaseline radiographic assessments documented as "not evaluable (NE)," rPFS was censored on the date of randomization.

Time frame:
From the date of randomization to the first objective evidence of rPD at any time or death (maximum duration was 26.6 months)
Reported as:
Median · months
Radiographic Progression-Free Survival (rPFS) Based on Independent Central Review (ICR) of Bone Scan According to Prostate Cancer Clinical Trials Working Group 2 (PCWG2) Criteria
monthsEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)
Radiographic Progression-Free Survival (rPFS) Based on Independent Central Review (ICR) of Bone Scan According to Prostate Cancer Clinical Trials Working Group 2 (PCWG2) CriteriaNA (NA to NA)19.4 (16.59 to NA)
Statistical analysis
  • Enzalutamide + Androgen Deprivation Therapy (ADT) vs Placebo + Androgen Deprivation Therapy (ADT) · Log Rank · p = <0.0001 (Stratified by volume of disease (low vs high) and prior docetaxel use (yes vs no) during screening period.) · Cox hazard ratio: 0.39 · 95% CI 0.30 to 0.50Stratified by volume of disease (low vs high) and prior docetaxel use (yes vs no) during screening period.
PrimaryrPFS Based on ICR of Bone Scan According to Protocol Assessment Criteria

rPFS was calculated as the time from the date of randomization to the first objective evidence of radiographic progression disease (rPD) at any time or death up to 24 weeks after study drug discontinuation without documented radiographic progression, whichever occurred first. rPD was defined as progressive disease by Response Evaluation Criteria in Solid Tumors version 1.1 for soft tissue disease or by appearance of 2 or more new lesions on bone scan compared to baseline for week 13 or the best response on treatment for week 25 or later assessments, as assessed by ICR or death. In participants with no rPFS event, rPFS was censored on the date of last evaluable radiographic assessment prior to the data analysis cutoff date. In participants with no baseline radiographic assessment, participants with no postbaseline radiographic assessments and participants with all postbaseline radiographic assessments documented as "not evaluable (NE)," rPFS was censored on the date of randomization.

Time frame:
From the date of randomization to the first objective evidence of rPD at any time or death (maximum duration was 26.6 months)
Reported as:
Median · months
rPFS Based on ICR of Bone Scan According to Protocol Assessment Criteria
monthsEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)
rPFS Based on ICR of Bone Scan According to Protocol Assessment CriteriaNA (NA to NA)19.0 (16.59 to 22.24)
Statistical analysis
  • Enzalutamide + Androgen Deprivation Therapy (ADT) vs Placebo + Androgen Deprivation Therapy (ADT) · Log Rank · p = <0.0001 · Cox proportional hazards model: 0.39 · 95% CI 0.30 to 0.50
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause. In participants still alive at the date of the analysis cutoff point, OS was censored on the last date the participant was known to be alive. OS was analyzed using Kaplan-Meier estimates.

Time frame:
From randomization to death due to any cause (maximum duration was 58.6 months)
Reported as:
Median · months
Overall Survival (OS)
monthsEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)
Overall Survival (OS)NA (NA to NA)NA (49.74 to NA)
Statistical analysis
  • Enzalutamide + Androgen Deprivation Therapy (ADT) vs Placebo + Androgen Deprivation Therapy (ADT) · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.66 · 95% CI 0.53 to 0.81Significance level is 0.04. Hazard ratio and 95 % CI are estimated by cox proportional hazards model.
SecondaryTime to Prostate Specific Antigen (PSA) Progression

Time to PSA progression was calculated as the time from the date of randomization to the first observation of PSA progression. A PSA progression was defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir, which was confirmed by a second consecutive value at least 3 weeks later. In participants with no PSA progression, time to PSA progression was censored on the date of the last PSA sample taken (or last value prior to 2 or more consecutive missed PSA assessments).

Time frame:
From the date of randomization to the first observation of PSA progression (maximum duration was 26.6 months)
Reported as:
Median · months
Time to Prostate Specific Antigen (PSA) Progression
monthsEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)
Time to Prostate Specific Antigen (PSA) ProgressionNA (NA to NA)NA (16.59 to NA)
Statistical analysis
  • Enzalutamide + Androgen Deprivation Therapy (ADT) vs Placebo + Androgen Deprivation Therapy (ADT) · Log Rank · p = <0.0001 (Stratified by volume of disease (low vs high) and prior docetaxel use (yes vs no) during screening period.) · Cox hazard ratio: 0.19 · 95% CI 0.13 to 0.26Stratified by volume of disease (low vs high) and prior docetaxel use (yes vs no) during screening period.
SecondaryTime to Start of New Antineoplastic Therapy

In participants with a new antineoplastic therapy initiated for prostate cancer after randomization, time to start of a new antineoplastic therapy was defined as the time interval from randomization to the date of the first dose administration of the first antineoplastic therapy. In participants with no new antineoplastic therapy initiated for prostate cancer after randomization, time to start of new antineoplastic therapy was censored on the last visit date or the date of randomization, whichever occurred last. Time to start of new antineoplastic therapy was analyzed using Kaplan-Meier estimates.

Time frame:
From randomization to the date of the first dose administration of the first antineoplastic therapy (maximum duration was 58.6 months)
Reported as:
Median · months
Time to Start of New Antineoplastic Therapy
monthsEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)
Time to Start of New Antineoplastic TherapyNA (NA to NA)40.5 (26.25 to NA)
Statistical analysis
  • Enzalutamide + Androgen Deprivation Therapy (ADT) vs Placebo + Androgen Deprivation Therapy (ADT) · Hazard ratio (hr): 0.38 · 95% CI 0.31 to 0.48Hazard ratio and 95 % CI are estimated by cox proportional hazards model.
SecondaryPSA Undetectable Rate

The PSA undetectable rate was defined as the percentage of participants with undetectable (\< 0.2 ng/mL) PSA values at any time during study treatment, of those participants with detectable (≥ 0.2 ng/mL) PSA values at baseline.

Time frame:
From baseline to detectable PSA values (maximum duration was 26.6 months)
Reported as:
Number · percentage of participants
PSA Undetectable Rate
percentage of participantsEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)
PSA Undetectable Rate68.1 (63.9 to 72.1)17.6 (14.4 to 21.2)
Statistical analysis
  • Enzalutamide + Androgen Deprivation Therapy (ADT) vs Placebo + Androgen Deprivation Therapy (ADT) · Cochran-Mantel-Haenszel · p = <0.0001 (Stratified by volume of disease (low vs high) and prior docetaxel use (yes vs no) during screening period.) · Difference in rate: 50.5 · 95% CI 45.3 to 55.7
SecondaryObjective Response Rate (ORR)

The ORR was calculated as the percentage of participants who achieved a completed response (CR) or a partial response (PR) (unconfirmed responses) in their soft tissue disease using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by ICR.

Time frame:
From date of randomization up to 26.6 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)
Objective Response Rate (ORR)83.1 (76.7 to 88.3)63.7 (56.3 to 70.7)
Statistical analysis
  • Enzalutamide + Androgen Deprivation Therapy (ADT) vs Placebo + Androgen Deprivation Therapy (ADT) · Cochran-Mantel-Haenszel · p = <0.0001 (Stratified by volume of disease (low vs high) and prior docetaxel use (yes vs no) during screening period.) · Difference in rate: 19.3 · 95% CI 10.4 to 28.2
SecondaryTime to Deterioration in Urinary Symptoms

In participants with deterioration, the time to deterioration was calculated as the time interval between randomization and the first deterioration in urinary symptoms at any postbaseline visit. A deterioration in urinary symptoms was defined as an increase in the Quality of Life Prostate-specific Questionnaire (QLQ-PR25) modified urinary symptoms. Subscale score by ≥ 50% of the standard deviation observed in the QLQ-PR25 modified urinary symptoms subscale score at baseline. Modified urinary symptoms subscale score consisted of 3-items (Q31 - Q33) from the QLQ-PR25, each scored from 1 (not at all) to 4 (very much). The total modified urinary symptoms subscale score ranges from 0-100, with higher scores represents a higher level of symptomatology/problems. In participants without deterioration in urinary symptoms, the time to deterioration in urinary symptoms was censored on the date the last urinary symptoms QLQ-PR25 score was calculable.

Time frame:
From date of randomization to the first deterioration in urinary symptoms at any postbaseline visit (maximum duration was 26.6 months)
Reported as:
Median · months
Time to Deterioration in Urinary Symptoms
monthsEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)
Time to Deterioration in Urinary SymptomsNA (19.35 to NA)16.8 (14.06 to NA)
Statistical analysis
  • Enzalutamide + Androgen Deprivation Therapy (ADT) vs Placebo + Androgen Deprivation Therapy (ADT) · Log Rank · p = 0.2162 (Stratified by volume of disease (low vs high) and prior docetaxel use (yes vs no) during screening period.) · Cox hazard ratio: 0.88 · 95% CI 0.72 to 1.08Stratified by volume of disease (low vs high) and prior docetaxel use (yes vs no) during screening period.
SecondaryTime to First Symptomatic Skeletal Event (SSE)

Time to first SSE was calculated as the time from randomization to the occurrence of the first SSE. An SSE was defined as radiation to bone, surgery to bone, clinically apparent pathological bone fracture, or spinal cord compression. In participants with no SSE, time to SSE was censored on the last visit date or the date of randomization, whichever occurred last.

Time frame:
From randomization to the occurrence of the first SSE (maximum duration was 26.6 months)
Reported as:
Median · months
Time to First Symptomatic Skeletal Event (SSE)
monthsEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)
Time to First Symptomatic Skeletal Event (SSE)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Enzalutamide + Androgen Deprivation Therapy (ADT) vs Placebo + Androgen Deprivation Therapy (ADT) · Log Rank · p = 0.0026 · Cox hazard ratio: 0.52 · 95% CI 0.33 to 0.80
SecondaryTime to Castration Resistance

Time to castration resistance was calculated as the time from randomization to the first castration-resistant event. A castration resistance event was defined as any of the following in the presence of castrate levels of testosterone (\< 50 ng/dL): radiographic disease progression, PSA progression or SSE, whichever occurred first. In participants with no documented castration resistance event, the time to castration resistance was censored on the latest date from: the date of last radiologic assessment, the last PSA sample taken prior to the start of any new prostate cancer therapy and prior to 2 or more consecutive missed PSA assessments (if applicable), and the last visit date performed.

Time frame:
From randomization to the first castration-resistant event (maximum duration was 26.6 months)
Reported as:
Median · months
Time to Castration Resistance
monthsEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)
Time to Castration ResistanceNA (NA to NA)13.9 (11.40 to 17.18)
Statistical analysis
  • Enzalutamide + Androgen Deprivation Therapy (ADT) vs Placebo + Androgen Deprivation Therapy (ADT) · Log Rank · p = <0.0001 · Cox hazard ratio: 0.28 · 95% CI 0.22 to 0.36
SecondaryTime to Deterioration of Quality of Life (QoL) in Functional Assessment of Cancer Therapy-Prostate (FACT-P)

Time to deterioration of QoL was calculated as the time interval from the date of randomization to the first date a decline from baseline of 10 points or more in the FACT-P total score was recorded. The FACT-P consists of 27 core items that assess participant function in 4 domains and 12 prostate cancer-related items grouped into 5 subscales as follows: physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing and prostate cancer subscale. Each item is rated on a 0 to 4 Likert-type scale. The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0 to 156), where high score represent better quality of life. In participants without FACT-P progression, the time to deterioration of QoL was censored on the date of the last FACT-P total score was calculable.

Time frame:
From the date of randomization to the first date a decline from baseline of 10 points or more in the FACT-P total score (maximum duration was 26.6 months)
Reported as:
Median · months
Time to Deterioration of Quality of Life (QoL) in Functional Assessment of Cancer Therapy-Prostate (FACT-P)
monthsEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)
Time to Deterioration of Quality of Life (QoL) in Functional Assessment of Cancer Therapy-Prostate (FACT-P)11.3 (11.04 to 13.83)11.1 (8.48 to 13.83)
Statistical analysis
  • Enzalutamide + Androgen Deprivation Therapy (ADT) vs Placebo + Androgen Deprivation Therapy (ADT) · Log Rank · p = 0.6548 · Cox hazard ratio: 0.96 · 95% CI 0.81 to 1.14
SecondaryTime to Pain Progression Based on Brief Pain Inventory-Short Form (BPI-SF)

Time to pain progression was defined as time from randomization to the first pain progression event. Pain progression was defined as an increase of ≥ 30% from baseline in the average BPI-SF pain severity score. BPI-SF contains 9 questions with rating scales from 0 (no pain/no interference) to 10 (worst pain/interferes completely). Total score was calculated as the average of each question. Higher scores represent a higher level of pain or interference. In participants with no pain progression event, time to pain progression was censored on the last visit date where BPI-SF was collected.

Time frame:
From randomization to the first pain progression event (maximum duration was 26.6 months)
Reported as:
Median · months
Time to Pain Progression Based on Brief Pain Inventory-Short Form (BPI-SF)
monthsEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)
Time to Pain Progression Based on Brief Pain Inventory-Short Form (BPI-SF)8.3 (8.25 to 10.91)8.3 (5.65 to 8.38)
Statistical analysis
  • Enzalutamide + Androgen Deprivation Therapy (ADT) vs Placebo + Androgen Deprivation Therapy (ADT) · Log Rank · p = 0.2715 · Cox hazard ratio: 0.92 · 95% CI 0.78 to 1.07

Adverse events

Collected over All-cause mortality: From randomization up to end of study duration (approximately 7 years) AEs: From first dose up to 30 days after last dose of study drug (maximum duration of treatment 7 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide + Androgen Deprivation Therapy (ADT)190/574 (33.1%)244/572 (42.7%)463/572 (80.9%)
Placebo + ADT197/576 (34.2%)128/574 (22.3%)401/574 (69.9%)
Placebo Cross-over Enzalutamide27/182 (14.8%)81/182 (44.5%)133/182 (73.1%)
Most frequent serious events
Showing 10 of 391
Most frequent serious events
EventEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + ADTPlacebo Cross-over Enzalutamide
CataractEye disorders0/5720/5745/182
Pulmonary embolismRespiratory, thoracic and mediastinal disorders6/5723/5745/182
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)13/5723/5744/182
FallInjury, poisoning and procedural complications12/5724/5742/182
Atrial fibrillationCardiac disorders10/5727/5742/182
Hepatic function abnormalHepatobiliary disorders1/5720/5743/182
Spinal compression fractureInjury, poisoning and procedural complications4/5720/5743/182
Cerebrovascular accidentNervous system disorders5/5721/5743/182
Deep vein thrombosisVascular disorders1/5721/5743/182
PneumoniaInfections and infestations9/5725/5741/182
Most frequent other events
Showing 10 of 25
Most frequent other events
EventEnzalutamide + Androgen Deprivation Therapy (ADT)Placebo + ADTPlacebo Cross-over Enzalutamide
Hot flushVascular disorders172/572131/57416/182
FatigueGeneral disorders147/57292/57443/182
ArthralgiaMusculoskeletal and connective tissue disorders147/57279/57419/182
Back painMusculoskeletal and connective tissue disorders89/57266/57429/182
HypertensionVascular disorders88/57236/57419/182
FallInjury, poisoning and procedural complications63/57216/57419/182
ConstipationGastrointestinal disorders61/57234/57412/182
COVID-19Infections and infestations29/5720/57418/182
DiarrhoeaGastrointestinal disorders56/57234/5749/182
NasopharyngitisInfections and infestations55/57233/57414/182

Baseline characteristics

All Randomized Participants

Age, Continuous
Age, Continuous(year)Enzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)Total
Mean69.5 ± 8.069.5 ± 8.469.5 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Enzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)Total
Female000
Male5745761150
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Enzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)Total
Hispanic or Latino463783
Not Hispanic or Latino5045141018
Unknown or Not Reported242549
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Enzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)Total
American Indian or Alaska Native000
Asian7580155
Native Hawaiian or Other Pacific Islander000
Black or African American8816
White466460926
More than one race000
Unknown or Not Reported252853
Volume of Disease
Volume of Disease(Participants)Enzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)Total
Low220203423
High354373727
Prior Docetaxel Therapy Use
Prior Docetaxel Therapy Use(Participants)Enzalutamide + Androgen Deprivation Therapy (ADT)Placebo + Androgen Deprivation Therapy (ADT)Total
None471474945
1 to 5 cycles141125
6 cycles8991180
08

Study locations

203 sites
  • Site US10016
    Homewood, Alabama 35209, United States
  • Site US10007
    Anchorage, Alaska 99503, United States
  • Site US10008
    Tucson, Arizona 85741, United States
  • Site US10034
    Fountain Valley, California 92708, United States
  • Site US10056
    La Jolla, California 92093, United States
  • Site US10026
    Santa Rosa, California 95403, United States
  • Site US10035
    Aurora, Colorado 80045, United States
  • Site US10050
    Denver, Colorado 80220, United States
  • Site US10048
    St. Petersburg, Florida 33710, United States
  • Site US10054
    Thomasville, Georgia 31792, United States
  • Site US10015
    Chicago, Illinois 60637, United States
  • Site US10043
    Springfield, Illinois 62703, United States
  • Site US10045
    Jeffersonville, Indiana 47130, United States
  • Site US10020
    West Des Moines, Iowa 50266, United States
  • Site US10055
    Kansas City, Kansas 66160-7233, United States
  • Site US10017
    Towson, Maryland 21204, United States
  • Site US10036
    Omaha, Nebraska 68114, United States
  • Site US10018
    Lawrenceville, New Jersey 08648, United States
  • Site US10025
    Newburgh, New York 12550, United States
  • Site US10029
    Syracuse, New York 13210, United States
  • Site US10068
    Charlotte, North Carolina 28207, United States
  • Site US10009
    Concord, North Carolina 28025, United States
  • Site US10014
    Durham, North Carolina 27710, United States
  • Site US10060
    Greenville, North Carolina 27834, United States
  • Site US10044
    Middleburg Heights, Ohio 44130, United States
  • Site US10011
    Lancaster, Pennsylvania 17604, United States
  • Site US10012
    Myrtle Beach, South Carolina 29572, United States
  • Site US10059
    Nashville, Tennessee 37208, United States
  • Site US10046
    Dallas, Texas 75231, United States
  • Site US10004
    Dallas, Texas 75390-9110, United States
  • Site US10040
    Virginia Beach, Virginia 23462, United States
  • Site US10002
    Burien, Washington 98166, United States
  • Site US10013
    Seattle, Washington 98101, United States
  • Site US10028
    Wenatchee, Washington 98801, United States
  • Site AR54002
    Rosario, Santa Fe Province S2000DSV, Argentina
  • Site AR54007
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Site AR54010
    Buenos Aires, C1180AAX, Argentina
  • Site AU61016
    Camperdown, New South Wales 2050, Australia
  • Site AU61007
    St Leonards, New South Wales 2065, Australia
  • Site AU61006
    Sydney, New South Wales, Australia
  • Site AU61009
    Tweed Heads, New South Wales 2485, Australia
  • Site AU61013
    Waratah, New South Wales 2298, Australia
  • Site AU61001
    Woodville South, South Australia 5011, Australia
  • Site AU61004
    Ballarat, Victoria, Australia
  • Site AU61015
    Clayton, Victoria, Australia
  • Site AU61017
    Parkville, Victoria, Australia
  • Site AU61008
    St Albans, Victoria, Australia
  • Site BE32001
    Mons, Hainaut, Belgium
  • Site BE32012
    Ghent, Oost-Vlaanderen, Belgium
  • Site BE32005
    Kortrijk, West-Vlaanderen, Belgium
  • Site BE32008
    Liège, Belgium
  • Site BE32007
    Yvoir, Belgium
  • Site CA15016
    Edmonton, Alberta T6G 1Z2, Canada
  • Site CA15024
    Abbotsford British Columbia, British Columbia V2S 3N6, Canada
  • Site CA15003
    Kelowna, British Columbia V1W 4V5, Canada
  • Site CA15022
    Kelowna, British Columbia V1Y 5L3, Canada
  • Site CA15010
    Brampton, Ontario L6T 4S5, Canada
  • Site CA15021
    Kingston, Ontario K7L 2V7, Canada
  • Site CA15013
    Oakville, Ontario L6H 3P1, Canada
  • Site CA15020
    Toronto, Ontario M5G 2M9, Canada
  • Site CA15023
    Granby, Quebec J2G 8Z9, Canada
  • Site CA15004
    Montreal, Quebec H3T1E2, Canada
  • Site CL56002
    Temuco, Araucania, Chile
  • Site CL56001
    Santiago, RM, Chile
  • Site CL56007
    Providencia, Santiago Metropolitan, Chile
  • Site CL56005
    Viña del Mar, Valparaiso, Chile
  • Site CL56004
    Reñaca, Viña Del Mar, Chile
  • Site CL56003
    Santiago, Chile
  • Site DK45005
    Aarhus, Central Jutland, Denmark
  • Site DK45008
    Holstebro, Central Jutland, Denmark
  • Site DK45002
    Copenhagen, Hovestaden, Denmark
  • Site DK45004
    Aalborg, North Denmark, Denmark
  • Site DK45003
    Herlev, Denmark
  • Site DK45001
    Odense C, Denmark
  • Site FI35802
    Helsinki, Etelä-Suomen Lääni, Finland
  • Site FI35804
    Pori, Länsi-Suomen Lääni, Finland
  • Site FI35803
    Seinäjoki, Länsi-Suomen Lääni, Finland
  • Site FI35801
    Tampere, Oulun Laani, Finland
  • Site FI35806
    Jakobstad, Finland
  • Site FI35805
    Oulu, Finland
  • Site FI35807
    Turku, Finland
  • Site FR33010
    Angers, Maine-et-Loire, France
  • Site FR33003
    Créteil, Val-de-Marne 94010, France
  • Site FR33006
    Bordeaux, France
  • Site FR33014
    Caen, 14076, France
  • Site FR33005
    La Roche-sur-Yon, France
  • Site FR33015
    Le Mans, France
  • Site FR33012
    Lille, France
  • Site FR33007
    Lyon, France
  • Site FR33011
    Nîmes, France
  • Site FR33001
    Pierre-Bénite, France
  • Site FR33009
    Quimper, France
  • Site FR33013
    Saint-Mandé, France
  • Site DE49002
    Freiburg im Breisgau, Baden-Wurttemberg, Germany
  • Site DE49004
    Nürtingen, Baden-Wurttemberg, Germany
  • Site DE49005
    Bonn, 53111, Germany
  • Site DE49014
    Hamburg, 20246, Germany
  • Site DE49013
    Heidelberg, 69120, Germany
  • Site IL97201
    Kfar Saba, Central District, Israel
  • Site IL97211
    Ẕerifin, Central District, Israel

Showing the first 100 of 203 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019 Nov 10;37(32):2974-2986. doi: 10.1200/JCO.19.00799. Epub 2019 Jul 22. PubMed 31329516 ↗
  • Armstrong AJ, Azad AA, Iguchi T, Stenzl A, Mottet N, Russell D, Rosales M, Haas GP, Saad F, Hussain M, Sternberg CN. Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. J Clin Oncol. 2026 May 10;44(14):1309-1322. doi: 10.1200/JCO-24-02829. Epub 2026 Mar 27. PubMed 41894648 ↗
  • Azad AA, Petrylak DP, Iguchi T, Shore ND, Villers A, Gomez-Veiga F, Alcaraz A, Alekseev B, Szmulewitz RZ, Holzbeierlein J, Rosbrook B, Ma J, Zohren F, El-Chaar NN, Haas GP, Stenzl A, Armstrong AJ. Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial. JAMA Netw Open. 2025 May 1;8(5):e258751. doi: 10.1001/jamanetworkopen.2025.8751. PubMed 40332939 ↗
  • Armstrong AJ, Azad AA, Conduit C, Haas GP, Bland C, Davis ID. Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies. Future Oncol. 2025 Jan;21(1):15-24. doi: 10.1080/14796694.2024.2408101. Epub 2024 Oct 15. PubMed 39404227 ↗
  • Armstrong AJ, Iguchi T, Azad AA, Villers A, Alekseev B, Petrylak DP, Szmulewitz RZ, Alcaraz A, Shore ND, Holzbeierlein J, Gomez-Veiga F, Rosbrook B, Zohren F, Haas GP, Gourgiotti G, El-Chaar N, Stenzl A. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. Eur Urol. 2023 Aug;84(2):229-241. doi: 10.1016/j.eururo.2023.04.002. Epub 2023 May 12. PubMed 37179240 ↗
  • Cella D, Ganguli A, Turnbull J, Rohay J, Morlock R. US Population Reference Values for Health-Related Quality of Life Questionnaires Based on Demographics of Patients with Prostate Cancer. Adv Ther. 2022 Aug;39(8):3696-3710. doi: 10.1007/s12325-022-02204-3. Epub 2022 Jun 22. PubMed 35731340 ↗
  • Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Shore ND, Gomez-Veiga F, Rosbrook B, Zohren F, Yamada S, Haas GP, Stenzl A. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022 May 20;40(15):1616-1622. doi: 10.1200/JCO.22.00193. Epub 2022 Apr 14. PubMed 35420921 ↗
  • Stenzl A, Dunshee C, De Giorgi U, Alekseev B, Iguchi T, Szmulewitz RZ, Flaig TW, Tombal B, Morlock R, Ivanescu C, Ramaswamy K, Saad F, Armstrong AJ. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. Eur Urol. 2020 Oct;78(4):603-614. doi: 10.1016/j.eururo.2020.03.019. Epub 2020 Apr 23. PubMed 32336645 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Oct 2018, 31 months.

Results were first posted in Jan 2020, 1 year 3 months after primary completion. A results delay was requested in Oct 2019.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 31 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2016
First posted
Feb 9, 2016
StartActual
Mar 9, 2016
Primary completionActual
Oct 14, 2018
CompletionActual
Jul 31, 2024
Results delay requested
Oct 1, 2019
Results first posted
Jan 21, 2020
Last update
Oct 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02677896
Collaborators
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Responsible party
Sponsor
First posted
Feb 9, 2016
Start date
Mar 9, 2016
Primary completion
Oct 14, 2018
Completion
Jul 31, 2024
Results posted
Jan 21, 2020
Last update
Oct 24, 2025

Study contacts

Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion